Funding round
Verdiva Bio Series A
Verdiva Bio, which works in cardiometabolic disorder therapeutics development in Guildford, raised $411M in a Series A round announced on 9 Jan 2025, led by Forbion and General Atlantic, at a $2.50B post-money valuation. 7 firms took part. It is Verdiva Bio's first venture round on record.
$411M
Amount raised
$2.50B
Post-money valuation
$2.09B pre-money
7
Investors
2 leads
16%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced Verdiva Bio at $2.50B after the new money. The $411M bought investors about 16% of the company. It is 47% of the $868M Verdiva Bio has raised in the venture rounds on record. Verdiva Bio raised again 8 months later: a Growth round of $457M in Sep 2025.
Verdiva Bio's funding rounds
Verdiva Bio has 2 venture rounds on record. This one is highlighted.
- Series A this round 9 Jan 2025, led by Forbion and General Atlantic $411M$2.50B post-money
- Growth 19 Sep 2025, led by Forbion and General Atlantic $457M
Investors
Who put money in
Forbion and General Atlantic led the round with 5 other firms.
Lead investors
- backs 58 venture-backed companies new investor
- General Atlantic backs 134 venture-backed companies new investor
Also in the round
- backs 109 venture-backed companies new investor
- backs 93 venture-backed companies new investor
- backs 16 venture-backed companies new investor
- Lilly Asia Ventures new investor
- backs 9 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, scaling operations and working capital.
- Product development
- Scaling operations
- Working capital
Comparable rounds
How it compares
107 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $27M, and this round was 16 times the median. The closest in time, other companies' Series A rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 9 Jan 2025 | $180M | not disclosed | Abingworth and Bain Capital Life Sciences |
| Pharmaceutical Products | 6 Jan 2025 | $93M | not disclosed | New Enterprise Associates |
| Pharmaceutical Products | 16 Jan 2025 | $33M | not disclosed | J2 Ventures and Global Health Investment Corporation |
| Pharmaceutical Products | 11 Jan 2025 | $25M | not disclosed | Remiges Ventures and Continuum Health Ventures |
| Pharmaceutical Products | 9 Jan 2025 | $19M | not disclosed | Novo Holdings and Pureos Bioventures |
| Pharmaceutical Products | 1 Jan 2025 | $7.3M | not disclosed | Aptar Pharma |
| Pharmaceutical Products | 9 Jan 2025 | $6.4M | not disclosed | Ki Tua Fund LP and Starbloom Primrose LP |
| Pharmaceutical Products | 19 Dec 2024 | $140M | not disclosed | OrbiMed and Avoro Capital Advisors |
Sources
Where this comes from
Reported by 3 sources.
Questions
Frequently asked
How much did Verdiva Bio raise in its Series A round?
Verdiva Bio raised $411M in its Series A round, announced in Jan 2025.
Who led Verdiva Bio's Series A round?
Forbion and General Atlantic led it, with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures and LYFE Capital.
What was Verdiva Bio's valuation at the Series A round?
$2.50B post-money ($2.09B pre-money).
How does it compare with other Series A rounds in Pharmaceutical Products?
107 Series A rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $27M, and this round was 16 times the median.
Did Verdiva Bio raise again after this round?
Yes: a Growth round in Sep 2025 of $457M.